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Abstract
Background: For more than a decade, microarrays have been a powerful and widely used tool to
explore the transcriptome of biological systems. However, the amount of biological material from
cell sorting or laser capture microdissection is much too small to perform microarray studies. To
address this issue, RNA amplification methods have been developed to generate sufficient targets
from picogram amounts of total RNA to perform microarray hybridisation.
Results: In this study, four commercial protocols for amplification of picograms amounts of input
RNA for microarray expression profiling were evaluated and compared. The quantitative and
qualitative performances of the methods were assessed. Microarrays were hybridised with the
amplified targets and the amplification protocols were compared with respect to the quality of
expression profiles, reproducibility within a concentration range of input RNA, and sensitivity. The
results demonstrate significant differences between these four methods.
Conclusion: In our hands, the WT-Ovation pico system proposed by Nugen appears to be the
most suitable for RNA amplification. This comparative study will be useful to scientists needing to
choose an amplification method to carry out microarray experiments involving samples comprising
only a few cells and generating picogram amounts of RNA.
Background
Gene expression profiling using microarray technology is
a powerful method to investigate the phenotype of com-
plex biological systems [1]. Over the last decade, develop-
ments by academic and private sectors have improved the
reproducibility, standardisation and accuracy, and have
decreased the cost of this technology. However, the main
drawback of this technology was the large amount of
input RNA needed to carry out microarray experiments,
preventing expression analysis on small samples. This
problem has been largely overcome thanks to RNA ampli-
fication methods. Standard target preparation protocols
now allow large-scale gene expression profiling to be per-
formed from nanogram quantities of input RNA. How-
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ever, cell selection technologies that allow the isolation of
1–100 cells such as cell-sorting methods [2] or laser cap-
ture microdissection (LCM) [3-5], have driven the devel-
opment for further reduction. Only a few protocols are
designed for the amplification of picogram amounts of
input RNA and allow the potential investigation of the
transcriptome of few cells isolated by cell-sorting tech-
niques or LCM.
The most routinely used amplification method is based
on linear amplification by in vitro transcription (IVT) of a
cDNA template into complementary RNA (cRNA), using
T7 RNA polymerase [6-8]. Several protocols based on this
technique have been developed and are commonly used
to perform gene expression profiling experiments using
microarrays [6,9-20]. Recently, a new RNA amplification
system based on the linear isothermal amplification of
double-stranded cDNA that encompasses a unique RNA/
DNA heteroduplex at one end using the RNA-dependent
DNA polymerase activity has been developed [21]. This
technique has been used to perform gene expression pro-
filing experiments [22-29].
We assume that the purification of total RNA from cul-
tured cells or tissue after isolation using these methods
can be largely method-, cell- or tissue-dependent. In this
study, to minimise this source of error and to focus on the
amplification method, a commercial source of total RNA,
i.e. human universal RNA, was used. We compared four
commercial RNA amplification protocols to the standard
target labelling procedure proposed by Affymetrix in side-
by-side experiments to evaluate the most suitable method
to perform gene expression profiling from picogram
amounts of input RNA on Affymetrix GeneChip microar-
rays. The following amplification protocols were com-
pared: i) Arcturus RiboAmp™ system, ii) Ambion
MessageAmp™, iii) Epicentre TargetAmp™, and iv) Nugen
WT-Amplification™ pico system. Protocols proposed by
Arcturus, Ambion and Epicentre are adapted from the IVT
method first described by Eberwine et al. [6-8]. The sys-
tem proposed by Nugen is based on the RNA-dependent
DNA polymerase activity [21]. Although amplification
methods have already been evaluated elsewhere
[15,24,26,30-33], no comparative study of RNA amplifi-
cation procedures from picogram amounts has been pub-
lished.
Results
Qualitative and quantitative analysis of the input total
RNA confirmed its high quality (Figure 1A).
Qualitative and quantitative analysis of amplification 
products
For each protocol, one RNA amplification was performed
from 250 pg and one from 500 pg of human universal
RNA by two operators in two independent laboratories. A
negative control (amplification without total RNA) and a
positive control (if available) were included in each exper-
imental batch. The quality of each amplified product
(cRNA or cDNA) was assessed using microfluidic electro-
phoresis (Figure 1C–F) and compared to the amplified
aRNA obtained from 2 μg and 100 ng RNA inputs follow-
ing the standard protocol proposed by Affymetrix (Figure
1B).
The size of the main population of aRNAs synthesised
according the protocol proposed by Ambion (Figure 1C)
ranged between 100 nt and 4000 nt with an average of
1000 nt which is shorter than the manufacturer's indi-
cated length. Moreover, an unexpected short-sized aRNA
population of 200 nt was consistently observed. The pop-
ulation of aRNA obtained using the Arcturus protocol
ranged in size between 100 and 2000 nucleotides (nt)
with an average of 500 nt, but aRNAs longer than 8000 nt
were systematically observed (Figure 1D). The aRNA pop-
ulation generated according to the Epicentre TargetAmp™
protocol (Figure 1E) ranged in size between 25 nt and
1000 nt, with an average of 200 nt, which is shorter than
indicated in the manufacturer's specifications. The elec-
trophoretic traces of the aRNA obtained during the dupli-
cate amplifications of 250 pg and 500 pg of starting total
RNA were also different. The size of cDNAs obtained
using the amplification method proposed by Nugen (Fig-
ure 1F) was distributed between 100 nt and 2000 nt (aver-
age: 500 nt) according to the manufacturer's protocol.
However, a discrete population cDNA of 100 nt was sys-
tematically observed, clearly corresponding to non-spe-
cific products that were also detected on amplification of
the negative control.
The quantities of aRNA and cDNA obtained after amplifi-
cation are presented in Table 1. Yields were sufficient to
perform target preparation and hybridisation according to
the manufacturers' protocols except for amplification per-
formed using Epicentre TargetAmp™ system. Moreover,
yields obtained with the protocols proposed by Epicentre
and Arcturus appeared to be laboratory-dependent and
non-reproducible in our hands (twofold changes in the
amounts of amplified cDNA). Regardless of the protocol
used, similar yields of about 2 μg of non-specific amplifi-
cation products were synthesised when amplification was
performed without RNA (negative controls).
Overall quality of expression profiles
After amplification, each labelled cRNA or cDNA target
was biotinylated, fragmented and hybridised on Affyme-
trix HG U133 plus 2.0 to assess the impact of each proto-
col on expression profiles. Raw .CEL files were normalised
using the MAS5 algorithm from Affymetrix, and metrics
for all hybridisations were analysed and compared (TableBMC Genomics 2009, 10:246 http://www.biomedcentral.com/1471-2164/10/246
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Quality of input RNA and targets synthesised from different amounts of input RNA Figure 1
Quality of input RNA and targets synthesised from different amounts of input RNA. A, Bioanalyzer electro-
phoretic profile of the diluted Universal Human Reference RNA used as input for all amplifications. This profile corresponds to 
a classical and non-degraded human RNA with two fine characteristic peaks corresponding to 18S and 28S RNAs. 8.4 corre-
sponds to the RNA Integrity Number (RIN) and reflects the high quality of this RNA B, electrophoretic profiles of cRNA 
obtained after one- and two-round Affymetrix amplification using 2 μg, and 100 ng of input RNA respectively or water as neg-
ative control. C, D, E, F, electrophoretic profiles of cRNA or cDNA obtained using Ambion (C), Arcturus (D), Epicentre (E) 
and Nugen (F) amplification systems from 250 pg and 500 pg of input RNA, or water as negative control.
500 pg H2O 250 pg
100 ng H2O 2 μg
B
C
A
RIN=8.4
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E
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2). Targets synthesised with each of the methods assessed
showed acceptable average background values compared
to Affymetrix specifications, ranging between 20 and 100.
Background values of chips hybridised with cDNA targets
(Nugen WT-Amplification™) were homogeneous and sig-
nificantly lower than those of the other chips. Percentage
of present calls (%P, i.e. expressed genes) ranged from
40% to 50%, as expected when analysing human univer-
sal RNA, except for the hybridisation performed from 500
pg of input RNA according to the Arcturus RiboAmp™
method (about 30% of present calls). Biases toward
amplification of 3' and 5' ends of GAPDH and β-Actin
were also computed (Table 2) in order to evaluate the effi-
ciencies of cDNA template synthesis and amplification
reactions. The 3'/5' ratios for housekeeping genes should
be at most 3 when one-round amplification is performed,
and at most 10 for two-round amplification procedures.
The 3'/5' ratios obtained were dramatically above the cut-
off values when targets were synthesised using the proto-
cols proposed by Arcturus, Ambion, and Epicentre but
remained acceptable (below 10) for cDNA targets pre-
pared according to the Nugen method.
Reproducibility and inter-system comparability
Raw signal distributions before (Figure 2A) and after nor-
malisation (Figure 2B) were analysed and compared. After
normalisation, the signal distributions of chips hybrid-
ised with all protocols were homogeneous and can be
compared. Note that the results obtained, before normal-
isation, with RNA amplified according to the Ambion
MessageAmp™ protocol highlight the discrepancies in sig-
nal distribution that appear to be batch- or laboratory-
dependent.
To assess the overall reproducibility of amplifications,
Pearson's correlation coefficients between technical repli-
cates were computed and averaged for each protocol (Fig-
ure 3A). The average of correlation coefficients for all
protocols was about 0.95 indicating high reproducibility
of measurements. Correlation coefficients between results
obtained from 250 pg and 500 pg of RNA input were also
averaged for each method to evaluate protocol reproduci-
bility and robustness across quantitative modulations of
RNA inputs (Figure 3A). Almost no difference was
observed for correlations between technical replicates and
Table 1: aRNA and cDNA yields obtained after amplification using universal RNA, positive and/or negative controls.
Protocol Sample Starting amount Amount of amplified material
Ambion Universal RNA 500 pg 88.1 μg
73.9 μg
Universal RNA 250 pg 65.1 μg
50.5 μg
Negative control 0 pg 2.5 μg
Arcturus Universal RNA 500 pg 34.3 μg
15.3 μg
Universal RNA 250 pg 45.6 μg
16.2 μg
Negative control 0 pg 1.9 μg
Positive control RNA 500 pg 24.3 μg
19.7 μg
Epicentre Universal RNA 500 pg 55.6 μg
6.3 μg
Universal RNA 250 pg 9.4 μg
Negative control 0 pg 1.9 μg
Positive control RNA 500 pg 5.1 μg
7.4 μg
Nugen Universal RNA 500 pg 7.6 μg
7.4 μg
Universal RNA 250 pg 6.9 μg
8.3 μg
Negative control 0 pg 1.8 μg
For each protocol, one RNA amplification was performed from 250 pg and one from 500 pg of human universal RNA by two operators in two 
independent laboratories. Arcturus and Epicentre kits contain an internal positive control RNA. These RNA were systematically included when 
performing experiments with those chemistries. Negative control experiments (amplification without total RNA) were also performed to evaluate 
template-independent nucleic acid synthesis.BMC Genomics 2009, 10:246 http://www.biomedcentral.com/1471-2164/10/246
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correlations between 250 pg and 500 pg of RNA input for
the Ambion and Nugen protocols, suggesting that the
amount of RNA input has little impact on expression data.
A lower correlation coefficient (0.924) was observed
between the results obtained with different amounts of
RNA input when using the Arcturus RiboAmp™ protocol.
The correlation of the gene expression data obtained with
each evaluated methods and the reference one-round and
two-round Affymetrix amplification protocols were also
compared to assess the value of each protocol (Figure 3B).
Not surprisingly, reproducibility within a given protocol
was higher than across protocols. Major discrepancies
between hybridisations of cDNA synthesised according to
the Nugen WT-Amplification™ protocol and aRNA pro-
duced according to the IVT amplification protocols (pro-
tocols proposed by Affymetrix, Ambion, Arcturus, and
Epicentre; Pearson's correlation coefficient of about 0.7)
were observed. Moreover, more marked discrepancies
were observed between data from Affymetrix one-round
IVT amplification and data from all two-round IVT ampli-
fications, than between each of the two-round IVT ampli-
fications. Not surprisingly, the most strongly correlated
results were obtained using similar amplification systems.
Further assessment of the Nugen protocol
The Nugen WT-Ovation™ pico system was further charac-
terised, as the overall best results were obtained using this
protocol. Additional amplifications and microarray
hybridisations from 50 pg, 100 pg and 1000 pg of input
RNA were performed in duplicate as previously. The
amounts of input RNA evaluated therefore ranged from
50 pg to 1 ng (50 pg, 100 pg, 250 pg, 500 pg, and 1000
pg). The quality of each amplified cDNA was assessed
(Figure 4). Not surprisingly, the discrete peak correspond-
ing to non-specific amplification products previously
observed in negative controls, increased relative to the
specific cDNA target quantity when the amount of input
RNA decreased. Amplification yields (Table 3) decreased
slightly with the amount of input RNA. Except for the
amplifications performed from 50 pg of input RNA, more
cDNA was generated than required for GeneChip hybrid-
Table 2: Comparison of hybridisation quality metrics of the evaluated RNA inputs and protocols.
Protocol RNA input Background Present Call β-Actin 3'/5' ratio GAPDH 3'/5' ratio
Ambion 500 pg 58.4 42% 139.1 11.2
32.0 48% 235.5 6.5
250 pg 58.4 38% 215.6 13.5
32.4 44% 123.3 7.6
Arcturus 500 pg 54.0 29% 96.3 25.2
52.4 30% 70.5 15.0
250 pg 32.7 37% 36.5 14.2
43.9 41% 33.3 9.4
Epicentre 500 pg 58.4 43% 30.9 11.4
-- - -
250 pg - - - -
-- - -
Nugen 500 pg 33.5 45% 6.6 1.1
35.7 49% 7.2 1.2
250 pg 31.5 39% 6.9 0.8
32.8 45% 10.6 1.3
Affymetrix, One-round amplification protocol 2 μg4 4 . 9
44.7
50%
49%
1.5
2.6
1.0
1.2
Affymetrix, Two-rounds amplification protocol 100 ng 66.7
54.7
52%
47%
12.2
12.8
1.3
1.8
'-': no hybridisation performed due to poor yield after amplification.
Targets were synthesised, in each laboratory (see Table 1), with the five protocols and hybridised to HG U133 Plus 2.0 array. A rapid analysis was 
performed with Expression Console (Affymetrix, MAS 5 normalisation).BMC Genomics 2009, 10:246 http://www.biomedcentral.com/1471-2164/10/246
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Box plots of signal intensities Figure 2
Box plots of signal intensities. A, raw data. B, data after MAS5 normalisation.
A
B BBMC Genomics 2009, 10:246 http://www.biomedcentral.com/1471-2164/10/246
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Statistical analysis of expression level measurements for assessing reproducibility and comparability of amplification chemistries Figure 3
Statistical analysis of expression level measurements for assessing reproducibility and comparability of amplifi-
cation chemistries. A, we calculated the Pearson's correlation coefficients between technical replicates (same chemistry, 
same amount of input RNA, but different laboratories). The correlation values were then averaged for each chemistry (grey 
bars). We also calculated correlation coefficients between results obtained from 250 pg and from 500 pg of RNA input (same 
chemistry, but different amount of RNA input) and averaged them for each chemistry in order to evaluate the robustness 
across quantitative variability of RNA input (black bars). Most Epicentre amplifications did not yield sufficient aRNA to carry 
out hybridisations, and Pearson's correlation coefficients could therefore not be calculated (*). B, Graphic representation of 
Pearson's correlation coefficients calculated for each pairwise comparison of all assays.
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isation according to the Nugen WT-Amplification™ pico
protocol (5 μg, Table 3). Amplified cDNA products,
including those containing less than 5 μg, were bioti-
nylated, fragmented and hybridised on Affymetrix HG
U133 plus 2.0 under the same experimental conditions as
those described previously. Hybridisation metrics were
analysed and compared as described previously (Table 3).
Average background values were low and homogeneous
with those obtained previously with 250 pg and 500 pg of
input RNA. The other metrics were within the expected
range according to the usual specifications for amplifica-
tions of 1000 pg, 500 pg and 250 pg, but the percentages
of present calls decreased for amplifications of 100 pg and
50 pg of RNA, and 3'/5' ratios for housekeeping genes
were significantly higher for amplifications performed
from 50 pg of RNA (Table 3). To further investigate the
Table 3: cDNA yields and hybridisation quality metrics of Nugen experiments.
RNA input Amount of amplified cDNA Background Present Call β-Actin 3'/5' ratio GAPDH 3'/5' ratio
1000 pg 10.6 μg 31.9 45.6% 8.7 1.3
6.1 μg 29.7 52.1% 6.0 1.0
500 pg 7.6 μg 33.5 45.1% 6.6 1.1
7.4 μg 35.7 48.6% 7.2 1.2
250 pg 6.9 μg 31.5 39.3% 6.9 0.8
8.3 μg 32.8 45.5% 10.6 1.3
100 pg 6.1 μg 29.8 37.8% 10.5 1.4
4.4 μg 32.4 29.4% 6.2 1.0
50 pg 3.5 μg 30.7 19.6% 23.6 1.5
4.5 μg 30.0 25.4% 11.1 1.2
0 pg 1.8 μg-- - -
Targets were synthesised in each laboratory with the Nugen protocol at five amount of input RNA and hybridised to HG U133 Plus 2.0 array. A 
rapid analysis was performed with Expression Console (Affymetrix, MAS 5 normalisation).
Quality of cDNA targets synthesised following Nugen protocol from different amounts of input RNA Figure 4
Quality of cDNA targets synthesised following Nugen protocol from different amounts of input RNA. Bioana-
lyzer electrophoretic profiles of cDNA targets obtained after the amplification of 50 pg, 100 pg, 250 pg, 500 pg, and 1 ng of 
total RNA using Nugen chemistry.
250pg 500pg 1000pg
100pg 50pgBMC Genomics 2009, 10:246 http://www.biomedcentral.com/1471-2164/10/246
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impact of RNA input amounts on expression data, Pear-
son's correlation coefficients between all experimental
data were computed (Figure 5). A weaker correlation was
observed for data obtained from the smallest amounts of
input RNA (50 pg and 100 pg).
To assess the sensitivity of Nugen system and to determine
whether it allowed the measurement of differential gene
expression, the expression profiles of two cell lines (SkBr3
and HCC38) were compared using the Nugen WT-Ampli-
fication™ pico system and the Affymetrix one-cycle IVT
amplification. 500 pg and 2 μg of RNA of each cell line
were amplified according to the protocols proposed by
Nugen and Affymetrix, respectively, and hybridised on
Affymetrix HG U133 plus 2.0 GeneChip. As expected,
Affymetrix and Nugen protocols showed similar yields of
reproducibility with correlation coefficients up to 0.90
between replicates (data not shown). Differential gene
expression analysis was performed for each system using
the present, absent, marginal increase, marginal decrease,
increase and decrease criteria proposed by Affymetrix and
implemented in GCOS software (Table 4). Although the
two systems allowed identification of the same number of
up- or down-regulated genes, only about 50% of these
genes were differentially expressed in the same direction
when using the other protocol. The other set of genes was
mostly non-modulated. The direction of differential
expression was divergent in only 0.3% of measurements
between the Nugen WT-Amplification™ pico system and
the Affymetrix one-round IVT amplification system.
Another evaluation of the differential gene expression
measurement has been performed. For each chemistry,
ratios of the expression values obtained for each cell line
were calculated and graphed (Figure 6). Although ratios
show dispersion with respect to the chemistry, no particu-
lar bias was noticed. In addition, differences in the direc-
tion of differential expression were observed for 4% of the
probesets (1100 over-expressed probesets with Nugen
and down-expressed with Affymetrix were observed and
inversely for 1166). Moreover, almost all of those
probesets show a low differential expression (absolute
value lower than 1, less than 2-fold over or lower expres-
sion).
Discussion
Gene expression profiling on several hundred cells iso-
lated by cell-sorting technologies, or by LCM prompts the
development of new amplification procedures. Over
recent years, academic, private sector and commercial
researchers have been developing tools and methods to
generate expression profiles from small amounts of bio-
logical material. Improvements have been made in all
steps of the process of expression profiling experiments
such as sample collection, RNA purification, or acquisi-
tion and analysis of expression data. Over the last few
years, improvements in RNA amplification methods now
allow the synthesis of sufficient targets to perform micro-
array hybridisation on as little as picogram amounts of
input RNA. In this study, we evaluated and compared four
commercial RNA amplification protocols using picogram
amounts of input RNA. This comparative study will be
useful to researchers when planning new experiments
involving samples derived from a few cells.
This comparative study was based on several assessments
of amplification products. First of all, electrophoresis was
performed and examined in combination with cRNA or
cDNA yields. This analysis is performed routinely prior to
hybridisation, as it provides an estimate of the overall
amplification performance. Unusual traces or insufficient
yield correspond to either abnormal input RNA, or ampli-
fication failure. The poor yield obtained with the protocol
proposed by Epicentre is due to amplification failures
since the quality of the commercial RNA has been
checked. Experimental errors might be the cause of these
failures. However, as amplifications were carried out in
duplicate by two experienced operators in two laborato-
ries, the quality of the batch and its reproducibility may be
responsible for these errors.
The overall size of aRNA, estimated by the electrophoretic
profile, has been previously described as a good metric
Reproducibility of expression data obtained using Nugen  chemistry across amounts of input RNA Figure 5
Reproducibility of expression data obtained using 
Nugen chemistry across amounts of input RNA. Pear-
son's correlation coefficients were computed and repre-
sented graphically for each pairwise comparison of assays. 
Lower correlations were observed for data obtained from 
smallest amounts of input RNA (50 pg and 100 pg).BMC Genomics 2009, 10:246 http://www.biomedcentral.com/1471-2164/10/246
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when looking at within-sample fidelity [26]. As expected,
a high level of consistency in amplified product sizes and
electrophoretic profiles was observed within each tech-
nology, since all amplifications were performed using the
same input RNA. The repeated observation of products of
very large size (8,000–12,000 nt) obtained with the Arctu-
rus RiboAmp™ kit are surprising and might be due to the
transcription of non-specific ligation of cDNA templates.
As for other microarray technologies, probes designed for
Affymetrix gene expression assay are biased towards the 3'
end of the transcripts: the length of the target is therefore
not a critical metric provided the targets cover the first 700
bases from the 3' end of the transcripts. However some
probes (10% at most) represent sequences over 600 bases
from the 3' end, and short amplification products may
therefore not address these probes. The impact of this
issue can be easily estimated by the 3'/5' ratios of house-
keeping genes. Affymetrix HG U133 plus 2.0 GeneChips
include probe sets selected in the 5' region of housekeep-
ing genes in addition to conventional probes within a
maximum of 600 nt from the 3' end. The signal intensity
ratio of the 3' probe over the 5' probe (3'/5' ratio) is a
good metric to evaluate the qualitative performance of
first strand cDNA synthesis and aRNA transcription (or
cDNA replication for Nugen WT-Amplification™). Abnor-
mally high ratios were obtained when using T7-IVT-based
amplification chemistries suggesting that the 3' biased
expression issue should be taken into consideration when
analysing these data. The lower 3'/5' ratios observed in the
Nugen WT-Amplification™ approach could be explained
by the fact that i) in addition to the conventional poly-T
priming for the initial reverse transcription, the system
proposed by Nugen also includes random priming, and
ii) amplification is performed in one cycle thus avoiding
shortening of targets at the 5' end by performing a random
primed reverse transcription of first-round amplified
aRNA.
Table 4: Comparison of differential gene expression data using Affymetrix one-round and Nugen chemistries.
Affymetrix Nugen
status # probsets % probsets status # probsets % probsets
D 7423 13.6% D 3908 52.6%
MD 127 1.7%
NC 3262 43.9%
MI 11 0.1%
I 115 1.5%
I 7057 12.9% D 140 2.0%
MD 12 0.2%
NC 2996 42.5%
MI 118 1.7%
I 3791 53.7%
MI 268 0.5% D 11 4.1%
MD 1 0.4%
NC 168 62.7%
MI 4 1.5%
I8 4 3 1 . 3 %
MD 317 0.6% D 94 29.7%
MD 5 1.6%
NC 203 64.0%
MI 1 0.3%
I 14 4.4%
NC 39610 72.4% D 3358 8.5%
MD 268 0.7%
NC 32811 82.8%
MI 224 0.6%
I 2949 7.4%
Targets were generated from RNAs of two cell lines using Affymetrix 1-round IVT and Nugen chemistries. After hybridisation, differential gene 
expression results were analysed. Status is defined as Decrease (D), Increase (I), Marginal Increase (MI), Marginal Increase (MI), and No Change 
(NC).BMC Genomics 2009, 10:246 http://www.biomedcentral.com/1471-2164/10/246
Page 11 of 15
(page number not for citation purposes)
The percentage of present call has been previously
described as a good metric when evaluating the sensitivity
of a method [30,34]. Gene expression analysis performed
on small amounts of input RNA, can be logically expected
to give a reduced sensitivity. However, only Arcturus Ribo-
Amp™ chemistry showed significantly reduced sensitivity
compared to the standard procedure. Poor sensitivity was
also observed when conducting experiments using Nugen
WT-Amplification™ system using the lowest amounts of
input RNA (50 pg and 100 pg), suggesting that the mini-
mum input limits of the protocol had been reached.
With respect to hybridisation specificities, the Nugen tech-
nology shows a fundamental difference as it generates a
single-stranded cDNA target whereas others protocols
yields cRNA targets. As RNA/DNA interactions are
stronger than DNA/DNA interactions, cDNA hybridisa-
tions should theoretically be more specific but also less
sensitive. However, the protocol proposed by Nugen was
not associated with decreased sensitivity and the lower
average background value of the chips hybridised with
cDNA targets (Nugen) suggests reduced non-specific tar-
get/background interactions but additional studies
should be conducted to evaluate the potential increased
specificity of the probe/target interaction and its biologi-
cal impact on expression profiling.
Practical criteria should be considered to choose an
amplification approach to carry out expression profiling
experiments. These include completion time, handling
difficulties and labour intensiveness. Major differences
were observed between the various protocols evaluated in
terms of these criteria. IVT-based amplifications (Ambion
MessageAmp™, Arcturus RiboAmp™, and Epicentre Target-
Amp™) involve numerous steps and are therefore time-
consuming and labour-intensive. However, the high qual-
ity of technical support and optimisation of chemistries
(most reagents are conveniently pre-dispensed and pre-
mixed) simplify the handling of the Ambion and Arcturus
systems. The Nugen technology is fundamentally different
from the IVT-based amplifications. Fewer steps are needed
to achieve amplification, and the process does not include
delicate RNA handling during the amplification process.
The Nugen WT-Amplification™ protocol is therefore
shorter and easier to complete, and consequently less
error-prone. Ultimately, investigators will need to com-
pare experimental results obtained by different laborato-
ries. Experimental variables (such as operator) on
expression data could be limited if fewer steps are needed
to achieve amplification.
When expression profiling experiments are performed on
just a few cells, it is currently impossible to strictly assess
the quality and quantity of the purified RNA. Even the
most modern and accurate spectrophotometers or micro-
fluidic-based electrophoresis chips require at least 100 pg
of RNA to characterise nucleic acids extracted from such
minute samples. The results presented here show that a
two-fold variation of the amount of input RNA had
almost no impact on the transcriptomes analysed when
starting with picogram amounts of RNA. Moreover, high
reproducibility within a given protocol (correlation coef-
ficient of about 0.95) was observed for amplifications that
were carried out in two different laboratories by two dif-
ferent operators. This shows that trained laboratories
could conduct amplifications with the technologies pro-
posed by Ambion, Arcturus, or Nugen and produce data
that could effectively be compared across laboratories
using the same amplification protocols. However, the
results obtained in this study indicate large variations
between different protocols. This suggests, as previously
Comparison of differential gene expression data using  Affymetrix one-round and Nugen chemistries Figure 6
Comparison of differential gene expression data 
using Affymetrix one-round and Nugen chemistries. 
Targets were generated from RNAs of two cell lines using 
Affymetrix 1-round IVT and Nugen chemistries. After 
hybridisation, differential gene expression results were nor-
malised (MAS5) and the expression ratio calculated for each 
probeset. Logarithm of ratios to the base 2 (Log2 ratios) 
were computed for each chemistries and graphed(X axis 
Nugen and Y axis Affymetrix). Differences in the direction of 
differential expression were only observed for 4% of the 
probesets (dots located in the upper-left quadrant and 
lower-right quadrant). Moreover, almost all of those 
probesets show a low differential expression (absolute value 
lower than 1, less than 2-fold over or lower expression). The 
slope of the regression line is 1.033 (p < 10-16) and it inter-
cepts the Y axis at -0.02 (p < 10-12). The Pearson's correla-
tion coefficient has been calculated between the expression 
ratios distribution (R = 0.321).
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shown, that i) when conducting expression profiling
experiments the same amplification protocol should be
used in order to maximize the comparability of the results
[26,31,33,35,36], and ii) that RNA amplification affects
the expression measurements [35,37-39]. However,
researchers who already have a large volume of Affymetrix
two-round amplification data, and who want to conduct
a project including comparison of these data, might
decide to choose the Ambion MessageAmp™ amplifica-
tion protocol despite its very high bias towards the 3' to 5'
ends, as expression profiles estimated according to this
protocol exhibited the best correlation with the results of
Affymetrix amplification (correlation coefficient of 0.89).
Amplifications were performed by two operators in two
different laboratories in order to mimic "real experimen-
tal conditions" of expression profiling. In our hands and
under these experimental conditions, Nugen WT-Amplifi-
cation™ pico protocol appeared the most suitable. Addi-
tional experiments were performed in order to further
assess this system. Amplifications were performed on
amounts of input RNA ranging from 50 pg to 1 ng to test
the system at the upper and lower limits of input amounts
corresponding to a few cells isolated by FACS or LCM. The
results obtained show that the overall quality, compara-
bility and reproducibility of expression measurements
were very good for RNA input amounts ranging from 250
pg to 1000 pg. The system was less efficient with 100 pg
and 50 pg of RNA inputs with respect to sensitivity and
reproducibility. It is important to analyse this result in the
light of manufacturer's specifications indicating that the
minimal RNA input of the system is 500 pg.
The results of a differential gene expression experiment
using Nugen WT-Amplification™ chemistry or Affymetrix
one-round IVT amplification were also compared. If we
strictly count the number of probesets with the same sta-
tus (Decrease, Increase, Marginal Increase, Marginal
Decrease or No Change) in both chimistries, discrepan-
cies were observed only for 25% of probesets. However
the direction of differential expression diverged in few
measurements. These results show that most genes have
similar differentially expressed patterns and that one
amplification protocol does not create an artificial varia-
bility of the measurements compared to the other. The
observed discrepancies do not appear to be due to the
decreased sensitivity of one of the two protocols because
the same proportion of genes was modulated when using
the Affymetrix and Nugen protocols. Although the effects
of RNA amplification on differential gene expression
measurements have been previously reported [26,35,37-
39], a large proportion of these discrepancies might be
due to fundamental differences between the two
approaches, such as the influence of the molecular nature
of the targets (RNA or DNA) on expression measurement,
or the use of random priming to synthesise double-
stranded cDNA templates.
The preservation of the relative abundance levels of gene
transcripts is an important issue when performing RNA
amplification prior to genome-wide expression measure-
ments. This issue has been widely studied in comparing
expression measurements i) from the amplification of dif-
ferent amounts of RNA [11,21,40], ii) from amplified and
unamplified materials [14,21,41,42], iii) using different
amplification procedures [11,15,26,43], iv) to a gold
standard amplification procedure[26,44], v) using differ-
ent expression evaluation methods such as quantitative-
reverse-transcription-Ploymerase-Chain-Reaction (qRT-
PCR) [21,26,36,43]. Most of these studies were performed
using IVT-based amplification methods. Those methods
were different from the ones evaluated in this report, and
were not optimised for picogram amounts of input RNA.
Only two studies were conducted using Nugen amplifica-
tion technology but not the WT-Amplification™ pico sys-
tem evaluated here [21,26]. The general conclusion that
could be drawn from these articles is that either IVT-based
or Nugen-like RNA amplifications were globally able to
maintain relative transcripts abundance with only slight
differences. However, it has been pointed out that, in
most of these reports, the statistical analyses or the com-
parison with qRT-PCR data were restricted only to subsets
of genes such as outliers or highly expressed genes
[31,37,38]. Furthermore, several studies have seriously
questioned the preservation of the relative transcript
abundance during RNA amplification. Sequence depend-
ent biases [35,37], and a drop of fidelity for low expressed
transcripts [10,39,45,46] have been demonstrated. In
addition, it has been shown that low expressed genes were
subject to stochastic fluctuations that increase as the sam-
ple size decreases [31,38,46]. However, we obtained high
correlations between technical replicates using either
Ambion, Arcturus or Nugen methods (Figure 3A). It
shows that no or negligible stochastic fluctuations occur
at these levels of input RNA (500 pg and 250 pg). On the
other hand, stochastic event could explain the lower
reproducibility observed for smaller amount of input
RNA (50 pg and 100 pg) using Nugen method.
Therefore, a) we do not recommend to perform amplifica-
tion from less than 250 pg of input RNA, and b) when it
is possible, researchers should try to increase the RNA
input quantity to at least 500 pg to be more confident in
the biological interpretation of the results, particularly
concerning low express transcripts.
Conclusion
In this study, we evaluated and compared four commer-
cial RNA amplification protocols using picogram
amounts of input RNA. An operational flow chart wasBMC Genomics 2009, 10:246 http://www.biomedcentral.com/1471-2164/10/246
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designed to evaluate the effects of laboratory and operator
intervariability on expression results. In our hands, the
WT-Ovation™ pico system proposed by Nugen appears
the most suitable for amplification and gene expression
analysis. The amplification method proposed by Nugen is
fast, easy to perform, and does not require several rounds
of amplification or exponential PCR cycles. It provides a
high quality expression profile that appears to allow iden-
tification of differentially expressed genes. Finally, the
reproducibility of the results of amplification across labo-
ratories and across amounts of RNA input indicates that
this system is an efficient tool to conduct gene expression
profiling experiments from LCM or cell-sorted isolated
samples.
Methods
RNA preparation and assessment
RNA derived from SkBr3 and HCC38 cells was purified
using the RNeasy Mini Kit (Qiagen) including on-column
DNase (Qiagen) digestion as described by the manufac-
turer's protocol. The Universal Human Reference RNA
(Stratagene) representing a pool of 10 different human
cell lines was used as control RNA.
After nucleic acid quantification using a ND-1000 spectro-
photometer (Nanodrop Technologies), all RNAs were
serially diluted in RNAse-free water to obtain a 250 pg/μL
stock solution. RNA quality was ensured by analysing sep-
aration trace of RNA using the RNA6000 PicoAssay for the
Bioanalyzer 2100 (Agilent). Aliquots were prepared and
stored at -80°C. The same RNA was used for all experi-
ments as starting RNA for amplification. Each aliquot was
used once.
When provided within the amplification kits, internal
RNA controls were also used as starting material (Mes-
sageAmp™ II aRNA Amplification (Ambion), RiboAmp™
HS RNA Amplification Kit (Arcturus)).
Logistics
All amplification experiments were carried out in dupli-
cate by two trained operators in two different laboratories
in order to assess the consistency and robustness of ampli-
fication and labelling protocols. Microarray hybridisa-
tions, quantitative and qualitative measurements were
performed by the same experienced technician on the
same instruments to ensure that expression level discrep-
ancies were only due to amplification and labelling proce-
dures.
Amplification and labelling of small RNA samples
RNA amplifications were performed using the following
kits: One- and two-round amplification kit (Affymetrix),
RiboAmp™ HS RNA Amplification Kit (Arcturus), Mes-
sageAmp™ II aRNA Amplification (Ambion), TargetAmp™
2-Round Aminoallyl-aRNA Amplification (Epicentre),
and WT-Amplification™ Pico (NuGEN). For all experi-
ments, the manufacturers' protocols were strictly fol-
lowed.
Briefly, the standard protocol described by Affymetrix
amplifies and produces after a single round T7 amplifica-
tion, more than 40 μg of labelled cRNA from 1–4 micro-
grams of total RNA. Total RNA is used for cDNA synthesis
using an oligo-dT-T7 primer. The cDNA is used as tem-
plate for double-strand DNA (dsDNA) synthesis and puri-
fication. Linear amplification and labelling of
complementary RNA (cRNA) is performed by in-vitro tran-
scription. When input RNA quantity is below standard
requirements, a two-round amplification protocol is per-
formed with 10–100 ng of total RNA. In this case, the first
IVT does not use any labelled nucleotide to generate unla-
belled cRNA. This cRNA is used for reverse transcription
(RT) with random primers, dsDNA synthesis and finally
labelled cRNA synthesis.
The MessageAmp™ II aRNA Amplification Kit (Ambion) is
based on the RNA amplification protocol described by
Eberwine et al. [6], and designed to generate sufficient
material to hybridise an Affymetrix Genechip. The proce-
dure to synthesise cRNA is similar to the Affymetrix two-
round amplification and consists of RT with oligo(dT)
primer bearing a T7 promoter followed by dsDNA and
unlabelled cRNA synthesis. A second round of amplifica-
tion is performed with random primers to generate DNA.
The sense DNA then undergoes second strand synthesis
and clean-up to become a template for the second in vitro
transcription (IVT) using labelled nucleotides.
RiboAmp HS version C (Arcturus RiboAmp HS protocol)
enables target synthesis from 100 pg to 500 ng. Version C
of RiboAmp HS is composed of two-round amplification
similar to the protocols proposed by Affymetrix or
Ambion. Reactions were performed according to the man-
ufacturer's protocol.
The TargetAmp 2-Round Aminoallyl-aRNA Amplification
Kit 1.0 (Epicentre) is designed to be an improvement of
the other linear T7 RNA amplification process described
above to produce microgram amounts of aminoallyl-
aRNA from as little as 10 pg of total RNA. Two rounds of
amplification combine two generations of SuperScript
Reverse Transcriptases from Invitrogen.
In contrast with other manufacturer protocols, the WT-
Ovation™ Pico RNA Amplification System (Nugen) is not
based on T7 polymerase cRNA synthesis. Nugen has
designed a technique called Ribo-SPIA™, which is a three-
step process that generates amplified cDNA from as little
as 500 picograms of total RNA[21]. First strand cDNA isBMC Genomics 2009, 10:246 http://www.biomedcentral.com/1471-2164/10/246
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prepared from total RNA using a unique first strand DNA/
RNA chimeric primer mix. The primers have a DNA por-
tion that hybridises either to the 5' portion of the poly(A)
sequence or randomly across the transcript. Reverse tran-
scriptase extends the 3' DNA end of each primer generat-
ing first strand cDNA/mRNA hybrid. Second strand cDNA
synthesis step generates double stranded products with
RNA-DNA heteroduplex at one end. The third step is the
DNA amplification, called SPIA™ amplification using a
specific DNA/RNA chimeric primer, DNA polymerase and
RNase H in a homogeneous isothermal assay that pro-
vides highly efficient amplification of DNA sequences.
RNase H is used to degrade RNA in the DNA/RNA heter-
oduplex at the 5' end of the first cDNA strand. This results
in the exposure of a DNA sequence that is available for
binding a second SPIA™ DNA/RNA chimeric primer. DNA
polymerase then initiates replication at the 3' end of the
primer, displacing the existing forward strand. The RNA
portion at the 5' end of the newly synthesised strand is
again removed by RNase H, exposing part of the unique
priming site for initiation of the next round of cDNA syn-
thesis. The process of SPIA™ DNA/RNA primer binding,
DNA replication, strand displacement and RNA cleavage
is repeated, resulting in rapid accumulation of cDNA with
a sequence complementary to the original mRNA.
The labeled cRNA targets are synthesised using the gene-
chip IVT labelling kit (Affymetrix) from dsDNA obtained
with Affymetrix and Arcturus protocols. TargetAmp
amplification products (Epicentre protocol) are labelled
using the Biotin-X-X-NHS kit (Epicentre). WT-Ovation™
Pico products (NuGEN) are labelled using the FL-Ova-
tion™ cDNA Biotin Module V2 (NuGEN). Each labeled
cRNA targets are synthesised according to manufacturer's
protocols.
Amplification products quantification and quality control
The quantity and quality of the amplified cRNA or cDNA
were assessed by a ND-1000 spectrophotometer (Nano-
drop Technologies), Agilent Bioanalyzer and RNA 6000
nanoChips (Agilent Technologies, Santa Clara, CA),
respectively.
Microarray hybridisation
Hybridisation mixtures were prepared according to
Affymetrix procedures to accommodate 10–20 μg of
labelled cRNA targets from Affymetrix, Arcturus, Ambion
and Epicentre amplifications, or 5 μg of cDNA targets
from NuGEN amplification. If less than 10 μg of cRNA or
5 μg of cDNA targets were generated, the entire quantity
of material was used as input. Human Genome U133 Plus
2.0 GeneChips (Affymetrix) were hybridised, revealed
and washed according to the Affymetrix protocol. Gene-
Chips were scanned using a 7 G scanner (Affymetrix) and
images (DAT files) were converted to CEL files using
GCOS software (Affymetrix). All of the microarray raw
data have been deposited in the Gene Expression Omni-
bus under the accession number GSE15398 http://
www.ncbi.nlm.nih.gov/geo/
Data Analysis
Data analysis was performed using expression console V
1.1 (Affymetrix) and genome analysis tools (Partek). Dif-
ferential gene expression analysis was performed using
GCOS software (Affymetrix).
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